Aurora Guerra-Tapia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aurora Guerra-Tapia has a total of 140 co-authors. Here are the top co-authors by number of shared publications:
E. González-Guerra
Universidad Complutense de Madrid, Facultad de Medicina, Madrid, Spain
3 shared publications- Carles Nieto
Laboratorio Reig Jofre S.A., Gran Capità, 10, Sant Joan Despí, 08970 Barcelona, Spain
2 shared publications - Carlos Ruíz
Laboratorio Reig Jofre, 08970 Sant Joan Despí, Spain
2 shared publications - David Palacios Martínez
Centro de Salud Almendrales, Dirección Asistencial Sur de Madrid, Servicio Madrileño de Salud - SERMAS, Madrid, España
2 shared publications - Helena Martínez
Laboratorio Reig Jofre, S.A. Barcelona Spain
2 shared publications Lola Bou
Consulta de Dermatología Barcelona Spain
2 shared publications
Latest Publications
- Open Access
- 24 June 2026
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 117 (10) , 104708
Dermatology in the Ingenious Gentleman Don Quijote of la Mancha
- 24 June 2026
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 117 (10) , 104708
Open AccessDermatology in the Ingenious Gentleman Don Quijote of la Mancha
- Open Access
- 15 May 2026
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 117 (9) , 104676
Suicide and Dermatology: Talking About What we Would Rather Not Talk About
- 15 May 2026
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 117 (9) , 104676
Open AccessSuicide and Dermatology: Talking About What we Would Rather Not Talk About
- Open Access
- 18 April 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (4) , 915
Shotgun Metagenomic Characterization of Acne Microbiota Before and After Treatment with a Topical Biotechnological Phytocomplex: Understanding Skin Dysbiosis
This study assessed the impact of a topical phytocomplex on the acne skin microbiota, encompassing bacterial, fungal, and phage communities. Skin samples obtained from participants exhibiting a positive response to the treatment were analyzed using high-throughput sequencing and bioinformatic approaches including taxonomic profiling, metagenome assembly, functional annotation, and phage identification. Results showed that after treatment, microbial diversity increased, reflecting a more balanced microbial composition. Cutibacterium acnes levels were reduced, particularly virulent IA1/IA2 phylotypes, whereas non-pathogenic or unclassified strains increased. Opportunistic pathogens such as Klebsiella pneumoniae were no longer detected, and beneficial genera including Psychrobacter and Dermabacter were enriched. Functional analysis showed reduced virulence- and biofilm-related pathways, alongside enhanced tryptophan metabolism, SCFA production, lipid synthesis, and riboflavin and folate biosynthesis. Fungal populations, dominated by Malassezia, became more evenly distributed, with notable post-treatment reductions in M. arunalokei, Exophiala spinifera, and Wickerhamomyces anomalus. Phage populations mirrored bacterial changes, with enrichment of Cutibacterium-associated phages post-treatment. These findings demonstrate that the phytocomplex promotes functional rebalancing of the skin microbiota by reducing pathogenic features while maintaining ecosystem stability. The inhibition of quorum sensing, potentially mediated by N-acyl-homoserine lactone acetylation, emerged from metabolic pathway annotation as a hypothetic key mechanism impairing bacterial communication and virulence associated with acne vulgaris.
- 18 April 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (4) , 915
Open AccessShotgun Metagenomic Characterization of Acne Microbiota Before and After Treatment with a Topical Biotechnological Phytocomplex: Understanding Skin Dysbiosis
This study assessed the impact of a topical phytocomplex on the acne skin microbiota, encompassing bacterial, fungal, and phage communities. Skin samples obtained from participants exhibiting a positive response to the treatment were analyzed using high-throughput sequencing and bioinformatic approaches including taxonomic profiling, metagenome assembly, functional annotation, and phage identification. Results showed that after treatment, microbial diversity increased, reflecting a more balanced microbial composition. Cutibacterium acnes levels were reduced, particularly virulent IA1/IA2 phylotypes, whereas non-pathogenic or unclassified strains increased. Opportunistic pathogens such as Klebsiella pneumoniae were no longer detected, and beneficial genera including Psychrobacter and Dermabacter were enriched. Functional analysis showed reduced virulence- and biofilm-related pathways, alongside enhanced tryptophan metabolism, SCFA production, lipid synthesis, and riboflavin and folate biosynthesis. Fungal populations, dominated by Malassezia, became more evenly distributed, with notable post-treatment reductions in M. arunalokei, Exophiala spinifera, and Wickerhamomyces anomalus. Phage populations mirrored bacterial changes, with enrichment of Cutibacterium-associated phages post-treatment. These findings demonstrate that the phytocomplex promotes functional rebalancing of the skin microbiota by reducing pathogenic features while maintaining ecosystem stability. The inhibition of quorum sensing, potentially mediated by N-acyl-homoserine lactone acetylation, emerged from metabolic pathway annotation as a hypothetic key mechanism impairing bacterial communication and virulence associated with acne vulgaris.
- Open Access
- 28 August 2024
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 23 (11) , 3616-3627
New clinical approach in facial mild–moderate acne: Re‐stabilization of skin microbiota balance with a topical biotechnological phytocomplex
Objectives: Dysbiosis of the skin microbiota has been identified as a key factor in the development of acne. This study was aimed to evaluate the effect of a facial cream gel containing a biotechnological phytocomplex, niacinamide and succinic acid on the bacterial diversity of subjects with mild–moderate acne and its clinical benefits due to microbiota changes.Methods: Open‐label, clinical study in 44 subjects with mild–moderate acne treated with a facial cream gel for 8 weeks. Bacterial diversity was analyzed by 16S rRNA gene sequencing of skin samples. Clinical effects were evaluated using the IGA acne severity scale, biometric measurements, and safety.Results: After 56 days of product's use, an increase in alpha and beta diversity was found (p < 0.01), with a decrease in the relative abundance of C. acnes (48.99% vs. 38.83%, p < 0.001). Regarding clinical results, a decrease in acne severity on the IGA scale (27.33%, p < 0.001), number of non‐inflammatory and inflammatory lesions (respectively: 31.12%, p = 0.05; 47.27%, p < 0.001), amount of sebum (89.00%, p < 0.01) and erythema (15.35%, p < 0.01), was found. [Correction added on 19 September 2024, after first online publication: In the preceding sentence, “42.27%” has been changed to “47.27%” in this version.] Responder analysis of the IGA score showed that 61.36% of patients improved by at least one point at day 56. The product was well tolerated throughout the study.Conclusions: The use of the facial cream gel on skin was effective in rebalancing the microbiota, inhibiting biofilm formation and other virulence factors, reducing the number of mild–moderate acne lesions and sebum secretion, and consequently improving acne's severity.
- 28 August 2024
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 23 (11) , 3616-3627
Open AccessNew clinical approach in facial mild–moderate acne: Re‐stabilization of skin microbiota balance with a topical biotechnological phytocomplex
Objectives: Dysbiosis of the skin microbiota has been identified as a key factor in the development of acne. This study was aimed to evaluate the effect of a facial cream gel containing a biotechnological phytocomplex, niacinamide and succinic acid on the bacterial diversity of subjects with mild–moderate acne and its clinical benefits due to microbiota changes.Methods: Open‐label, clinical study in 44 subjects with mild–moderate acne treated with a facial cream gel for 8 weeks. Bacterial diversity was analyzed by 16S rRNA gene sequencing of skin samples. Clinical effects were evaluated using the IGA acne severity scale, biometric measurements, and safety.Results: After 56 days of product's use, an increase in alpha and beta diversity was found (p < 0.01), with a decrease in the relative abundance of C. acnes (48.99% vs. 38.83%, p < 0.001). Regarding clinical results, a decrease in acne severity on the IGA scale (27.33%, p < 0.001), number of non‐inflammatory and inflammatory lesions (respectively: 31.12%, p = 0.05; 47.27%, p < 0.001), amount of sebum (89.00%, p < 0.01) and erythema (15.35%, p < 0.01), was found. [Correction added on 19 September 2024, after first online publication: In the preceding sentence, “42.27%” has been changed to “47.27%” in this version.] Responder analysis of the IGA score showed that 61.36% of patients improved by at least one point at day 56. The product was well tolerated throughout the study.Conclusions: The use of the facial cream gel on skin was effective in rebalancing the microbiota, inhibiting biofilm formation and other virulence factors, reducing the number of mild–moderate acne lesions and sebum secretion, and consequently improving acne's severity.
- Open Access
- 23 July 2024
- Published by Wiley in Skin Research and Technology
- Vol. 30 (7) , e13806
A new topical biotechnological phytocomplex for truncal mild‐moderate acne restores skin microbiota balance
Background: The disruption of the microbial community or dysbiosis alters the functional composition, metabolic activity, and local distribution of the microbiota leading the development of acne. The aim of this study is to evaluate the effect of a lotion containing a biotechnological phytocomplex, niacinamide, and succinic acid in the bacterial diversity of subjects with truncal mild‐moderate acne and its clinical benefits due to microbiota changes. Materials and Methods: Open, clinical study in 43 subjects with truncal mild‐moderate acne treated with a lotion for 8 weeks. Bacterial diversity was analyzed by 16S rRNA gene sequencing of skin samples. Clinical effects were evaluated through IGA acne severity scale, biometric measurements, and safety. Results: After 56 days of product's use, an increase in richness alpha diversity was found ( p = 0.005), with a decrease in Cutibacterium acnes relative abundance (66.43% vs. 58.11%, p = 0.009). The clinical results showed a decrease in IGA score (27.59% decrease; p = 0.001), the inflammatory lesions (52.12% decrease, p = 0.006) and erythema (18.33% decrease, p = 0.007), and desquamation index (63.83% decrease, p = 0.02). The responder analysis of the IGA score showed that 60.47% of patients improved by at least one point at day 56. The product was well tolerated along the study. Conclusion: The use of the lotion on acneic skin was effective on rebalancing the microbiota, inhibiting biofilm formation and other virulence factors, reducing erythema and desquamation, and improving acne's severity.
- 23 July 2024
- Published by Wiley in Skin Research and Technology
- Vol. 30 (7) , e13806
Open AccessA new topical biotechnological phytocomplex for truncal mild‐moderate acne restores skin microbiota balance
Background: The disruption of the microbial community or dysbiosis alters the functional composition, metabolic activity, and local distribution of the microbiota leading the development of acne. The aim of this study is to evaluate the effect of a lotion containing a biotechnological phytocomplex, niacinamide, and succinic acid in the bacterial diversity of subjects with truncal mild‐moderate acne and its clinical benefits due to microbiota changes. Materials and Methods: Open, clinical study in 43 subjects with truncal mild‐moderate acne treated with a lotion for 8 weeks. Bacterial diversity was analyzed by 16S rRNA gene sequencing of skin samples. Clinical effects were evaluated through IGA acne severity scale, biometric measurements, and safety. Results: After 56 days of product's use, an increase in richness alpha diversity was found ( p = 0.005), with a decrease in Cutibacterium acnes relative abundance (66.43% vs. 58.11%, p = 0.009). The clinical results showed a decrease in IGA score (27.59% decrease; p = 0.001), the inflammatory lesions (52.12% decrease, p = 0.006) and erythema (18.33% decrease, p = 0.007), and desquamation index (63.83% decrease, p = 0.02). The responder analysis of the IGA score showed that 60.47% of patients improved by at least one point at day 56. The product was well tolerated along the study. Conclusion: The use of the lotion on acneic skin was effective on rebalancing the microbiota, inhibiting biofilm formation and other virulence factors, reducing erythema and desquamation, and improving acne's severity.
- Open Access
- 1 July 2021
- Published by Editorial Glosa, S.L. in Más dermatología
- No. 35,p. 7-16
El paciente de dermatología estética: factores psicológicos
- 1 July 2021
- Published by Editorial Glosa, S.L. in Más dermatología
- No. 35,p. 7-16
Open AccessEl paciente de dermatología estética: factores psicológicos
- Open Access
- 1 December 2019
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 12, 943-951
Challenges and Solutions in Oral Isotretinoin in Acne: Reflections on 35 Years of Experience
Acne vulgaris affects more than 80% of adolescents and young adults and forms a substantial proportion of the dermatologist’s and general practitioner’s caseload. Severity of symptoms varies but may result in facial scarring and psychological repercussions. Oral isotretinoin is highly effective but can only be prescribed by specialists. Side effects are recognized and mostly predictable, ranging from cosmetic effects to teratogenicity. These can affect patients’ quality of life and treatment adherence. This article provides a commentary on 4 key areas: the use of oral isotretinoin vs oral antibiotics, including the importance of early recognition of nonresponse to treatment, the psychological effects of acne and isotretinoin treatment, the side effects of isotretinoin therapy, and cosmetic treatment options that can help alleviate predictable side effects. The authors, who have all participated in various international expert groups, draw on relevant literature and their extensive professional experience with oral isotretinoin in the treatment of acne. The aim of this article is to provide an informative and practical approach to managing oral isotretinoin treatment in patients with acne, to help optimize treatment of this skin disease.
- 1 December 2019
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 12, 943-951
Open AccessChallenges and Solutions in Oral Isotretinoin in Acne: Reflections on 35 Years of Experience
Acne vulgaris affects more than 80% of adolescents and young adults and forms a substantial proportion of the dermatologist’s and general practitioner’s caseload. Severity of symptoms varies but may result in facial scarring and psychological repercussions. Oral isotretinoin is highly effective but can only be prescribed by specialists. Side effects are recognized and mostly predictable, ranging from cosmetic effects to teratogenicity. These can affect patients’ quality of life and treatment adherence. This article provides a commentary on 4 key areas: the use of oral isotretinoin vs oral antibiotics, including the importance of early recognition of nonresponse to treatment, the psychological effects of acne and isotretinoin treatment, the side effects of isotretinoin therapy, and cosmetic treatment options that can help alleviate predictable side effects. The authors, who have all participated in various international expert groups, draw on relevant literature and their extensive professional experience with oral isotretinoin in the treatment of acne. The aim of this article is to provide an informative and practical approach to managing oral isotretinoin treatment in patients with acne, to help optimize treatment of this skin disease.
- 1 December 2019
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 110 (10) , 819-829
Fase final de la validación transcultural al español de la escala Hair Specific Skindex-29: sensibilidad al cambio y correlación con la escala SF-12
- 1 December 2019
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 110 (10) , 819-829
Fase final de la validación transcultural al español de la escala Hair Specific Skindex-29: sensibilidad al cambio y correlación con la escala SF-12
- 1 December 2019
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 110 (10) , 800-808
Diagnóstico y tratamiento del síndrome de piel sensible: un algoritmo para la práctica clínica habitual
- 1 December 2019
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 110 (10) , 800-808
Diagnóstico y tratamiento del síndrome de piel sensible: un algoritmo para la práctica clínica habitual
- 1 June 2018
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 109 (5) , 424-431
Validación de una adaptación transcultural al idioma español de la escala Hair Specific Skindex-29
- 1 June 2018
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 109 (5) , 424-431
Validación de una adaptación transcultural al idioma español de la escala Hair Specific Skindex-29